Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- GLPG
- Price
- 30.66
- Stock movement up
- +0.42 (1.39%)
- Company name
- Galapagos NV ADR
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.02B
- Ent value
- 3.20B
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 9.79
- Forward P/E
- 264.31
- PEG
- -
- EPS growth
- -
- 1 year return
- 14.87%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-11-21
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
GLPG does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 9.79 |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | 107.25 |
| EV to EBITDA | 169.66 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | -356.30 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 65.90M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | 0.12 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 75.74M |
| Net receivables | 91.26M |
| Total current assets | 3.72B |
| Goodwill | 0.00 |
| Intangible assets | 8.72M |
| Property, plant and equipment | 0.00 |
| Total assets | 4.13B |
| Accounts payable | 118.24M |
| Short/Current long term debt | 8.81M |
| Total current liabilities | 430.71M |
| Total liabilities | 1.25B |
| Shareholder's equity | 0.00 |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 30.19 |
| Daily high | 30.85 |
| Daily low | 30.19 |
| Daily Volume | 88K |
| All-time high | 274.03 |
| 1y analyst estimate | 30.59 |
| Beta | -0.05 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 24 Feb 2026 |
Downside potential
Loading...
Downside potential data
| GLPG | S&P500 | |
| Current price drop from All-time high | -88.81% | -4.13% |
| Highest price drop | -91.72% | -19.00% |
| Date of highest drop | 4 Feb 2025 | 8 Apr 2025 |
| Avg drop from high | -89.55% | -2.73% |
| Avg time to new high | - | 6 days |
| Max time to new high | 282 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
2.02B
Marketcap category
Mid-cap
Description
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Employees
704
Website
Investor relations
-
SEC filings
CEO
Onno van de Stolpe
Country
USA
City
Mechelen
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page